Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether nonsteroidal antiinflammatory drug lornoxicam in combination with low dose aspirin (100mg/day) is effective and safe in patients with Acute Coronary Syndrome without persistent ST-segment elevation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation; Central Clinical Hospital with Outpatient Health Center of Business Administration for the President of Russian Federati
• Treatments: Lornoxicam; Piroxicam

Criteria

Inclusion Criteria:

1. Unstable angina verified during first 48 hours after admitting to the hospital or

2. Acute Miocardial infarction without St-segment elevation verified during first 48 hours after admitting to the hospital

Exclusion Criteria:

1. High risk of bleeding of any location

2. Any kind of acute and active inflammatory process (excluding acute coronary syndrome)

3. Aspirin or NSAID Intolerability

4. No informed consent

5. Acute peptic stomach or duodenum ulcer

6. Acute or chronic renal failure (serum creatinin >300 mmol/l)

7. Acute cerebrovascular bleeding